– Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg – Ongoing analyses of AB-452, a novel orally-available RNA destabilizer, with… Read More
VANCOUVER, BC – Onestep Laboratories, a B.C. based biotech company that specializes in developing and producing raw material for immunoassay and other assays, has successfully developed a stable formula for… Read More
Warminster, PA. – Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark Murray, Arbutus’ President and CEO, will present a… Read More
Warminster, PA. – Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and year-end 2018 financial… Read More
Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked… Read More
